Tricyclo Ring System Having The Thiazole Ring As One Of The Cyclos Patents (Class 548/150)
  • Patent number: 9388198
    Abstract: The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, n and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 12, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg, Simon Stamm
  • Patent number: 9223211
    Abstract: Provided is a photosensitive resin composition having high sensitivity and storage stability.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 29, 2015
    Assignee: FUJIFILM Corporation
    Inventors: Kyouhei Sakita, Shinji Fujimoto, Mikio Nakagawa, Kenta Yamazaki
  • Publication number: 20150148546
    Abstract: Provided is a photosensitive resin composition having high sensitivity and storage stability.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 28, 2015
    Applicant: FUJIFILM Corporation
    Inventors: Kyouhei SAKITA, Shinji FUJIMOTO, Mikio NAKAGAWA, Kenta YAMAZAKI
  • Patent number: 9040713
    Abstract: The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 26, 2015
    Assignee: EMORY UNIVERSITY
    Inventor: Keqiang Ye
  • Patent number: 9024037
    Abstract: Diphenylamine-benzobisthiazole-diphenylamine monomers having two-photon absorption cross-sections and high solubility in organic solvents are provided. Also provided are the corresponding organo-soluble, wholly conjugated and two-photon absorbing benzobisthiazole-triarylamine polymers.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 5, 2015
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Loon-Seng Tan, Ramamurthi Kannan, Matthew Dalton
  • Publication number: 20150010504
    Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.
    Type: Application
    Filed: February 9, 2013
    Publication date: January 8, 2015
    Applicant: Lupin Limited
    Inventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 8895591
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: November 25, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Patent number: 8884029
    Abstract: A photoelectric conversion device capable of improving conversion efficiency is provided. The photoelectric conversion device includes a work electrode, an opposed electrode, and an electrolyte-containing layer. In the work electrode, a metal oxide semiconductor layer supporting a dye is provided. The dye contains a cyanine compound that has a methine chain, an indolenine skeleton bonded with both ends of the methine chain, and anchor groups introduced to a nitrogen atom included in the indolenine skeleton. Electron injection efficiency to the metal oxide semiconductor layer is improved, and the dye is hardly exfoliated from the metal oxide semiconductor layer.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: November 11, 2014
    Assignee: Adeka Corporation
    Inventors: Junji Tanabe, Atsushi Monden, Masahiro Shinkai, Mitsuhiro Okada, Toru Yano, Yohei Aoyama, Yusuke Kubota
  • Publication number: 20140304842
    Abstract: Novel red-shifted luciferin derivatives and uses of those compounds are provided.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 9, 2014
    Applicant: PROMEGA CORPORATION
    Inventor: Carolyn Woodroofe Hitko
  • Patent number: 8779154
    Abstract: The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: July 15, 2014
    Inventors: Qinglin Che, Nha Huu Vo, Shoujun Chen
  • Publication number: 20130324537
    Abstract: The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
    Type: Application
    Filed: November 21, 2012
    Publication date: December 5, 2013
    Applicants: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, Abbott Laboratories, Andrea Hager-Wernet
  • Publication number: 20130267543
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: November 8, 2011
    Publication date: October 10, 2013
    Applicants: CHAPERONE THERAPEUTICS, INC., DUKE UNIVERSITY
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Patent number: 8552037
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: October 8, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Patent number: 8512881
    Abstract: Disclosed are an organic material including a compound represented by the following Chemical Formula 1, and an organic light emitting device including the organic material. In Chemical Formula 1, A is an oxygen (O) atom or a sulfur (S) atom, M is a divalent or trivalent metal atom, R1 is an organic group, Y is a substituted or unsubstituted condensed polycyclic aromatic group, Z1 to Z4 are independently a carbon atom or a nitrogen atom, m is an integer ranging from 1 to 4, and n is 2 or 3.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: August 20, 2013
    Assignee: Samsung Display Co., Ltd.
    Inventors: Yuji Hamada, Kwan-Hee Lee
  • Publication number: 20130178505
    Abstract: Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.
    Type: Application
    Filed: June 28, 2011
    Publication date: July 11, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michael Chorev, Bertal Huseyin Aktas, Jose A. Halperin, Gerhard Wagner
  • Publication number: 20130178629
    Abstract: The present invention provides a series of 2,3-bis(hydroxymethyl)-4H-benzo[d]pyrrolo-[1,2-a]thiazoles and 1,2-bis(hydroxymethyl)indolizino[6,7-b]indole derivatives and their bis(alkylcarbamates) derivatives. These derivatives were designed as bi-functional DNA cross-linking agents. The in vitro cytotoxicity study of these compounds revealed that they exhibit significant anti-proliferative activity in inhibiting human lymphoblastic leukemia and various solid tumor cell growth. The compounds also exhibit therapeutic efficacy against human breast carcinoma and lung cancer in xenograft model. The compounds generally possess potent antitumor activity to kill various human solid tumors and have high potential for clinical applications.
    Type: Application
    Filed: July 16, 2012
    Publication date: July 11, 2013
    Applicant: Academia Sinica
    Inventors: Tsann-Long Su, Ting-Chao Chou, Te-Chang Lee
  • Publication number: 20130158082
    Abstract: The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I.
    Type: Application
    Filed: September 27, 2011
    Publication date: June 20, 2013
    Applicant: EMORY UNIVERSITY
    Inventor: Keqiang Ye
  • Publication number: 20130143910
    Abstract: A method and composition for treating cancer cells that targets fructose-1,6-biphosphataseenzymes (FBPs, type 1 and type 2) and/or their respective pathways. In one embodiment, inhibitors of FBPs or FBPs pathways are administered to a patient to treat brain cancer metastasis. In another embodiment, the present invention is particularly well suited for treating cancer cells that generally survive under glucose-independent conditions, or any other condition where cancer cells produce glucose via FBPs mediated pathways.
    Type: Application
    Filed: November 14, 2012
    Publication date: June 6, 2013
    Inventor: Zhang Weihua
  • Patent number: 8410152
    Abstract: Described are compounds having a thiazolhydrazide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said thiazolhydrazide compounds can be used for prophylaxis and/or treatment of neurodegenerative diseases and conditions.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: April 2, 2013
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e. V., Technische Universitat Darmstadt, The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
    Inventors: Eckhard Mandelkow, Eva-Maria Mandelkow, Markus Pickhardt, Jacek Biernat, David George Lloyd, Boris Schmidt, Gregor Larbig
  • Publication number: 20130079374
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Application
    Filed: October 23, 2012
    Publication date: March 28, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITE
  • Patent number: 8349879
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: January 8, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Patent number: 8318784
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: November 27, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Patent number: 8309738
    Abstract: Methods for the preparation of indene-based thiazolidinethiones are provided comprising contacting 1-amino-2,3-dihydro-1H-inden-2-ol, or a substituted derivative thereof, with an acid under suitable reaction conditions to provide a first intermediate; and contacting the first intermediate with an alkali xanthate in the presence of an alkali hydroxide under suitable reaction conditions to provide a compound of formula (III), wherein R1-R8 are defined herein.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 13, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Horacio F. Olivo, Antonio Victor Osorio Lozada
  • Publication number: 20120277325
    Abstract: The present invention relates to novel pyrimidine derivatives and their use in perfume compositions. The novel pyrimidine derivatives of the present invention are represented by the following formula: wherein m and n are integers that when m is 0, n is 1; when m is 1, n is 0 or 1; or when m is 2, n is 0; wherein (CH)m and (CH)n are each independently optionally substituted with a substituent selected from the group consisting of methyl and ethyl; wherein X is selected from the group consisting of N, O, and S; and wherein R1 and R2 each independently represent H or a hydrocarbon group, or R1 and R2 together represent a fused ring or a ring system, with the proviso that when R1 is H, R2 is not H.
    Type: Application
    Filed: July 3, 2012
    Publication date: November 1, 2012
    Inventors: Robert P. Belko, Paul D. Jones, Anthony T. Levorse, JR., Michael G. Monteleone, Anubhav P.S. Narula, Franc T. Schiet
  • Patent number: 8242152
    Abstract: This invention relates to a pharmaceutical composition containing 4-[(4-thiazolyl)phenoxyl]alkoxy-benzamidine derivatives expressed by the following formula 1 for the prophylaxis and treatment of osteoporosis and more particularly, to the use of 4-{5-[4-(5-isoproply-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine expressed by the following formula 1 as a pharmaceutical composition for the prophylaxis and treatment of osteoporosis.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: August 14, 2012
    Assignee: Dong Wha Pharmaceutical Co., Ltd.
    Inventors: Hong-Suk Suh, Jin Soo Lee, Pan-Soo Kim, Yun-Ha Hwang, Jei Man Ryu, Yong-Ho Chung, Eun-Joo Kim, Do-Hui Kim, Yong-Youp Park
  • Publication number: 20120196852
    Abstract: The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using various naphthoquinone, hydroxyquinonline, and naphthothiazole compounds.
    Type: Application
    Filed: August 5, 2010
    Publication date: August 2, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jun O. Liu, Omonike Arike Olaleye, Shridhar Bhat
  • Patent number: 8227496
    Abstract: A method of treating osteoporosis comprising administering to a subject a composition comprising a compound, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof, is described. A method of inhibiting osteoclast activity and stimulating osteoblast activity in a subject also is described.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Dong Wha Pharmaceutical Co., Ltd
    Inventors: Hong-Suk Suh, Jin Soo Lee, Pan-Soo Kim, Yun-Ha Hwang, Jei Man Ryu, Yong-Ho Chung, Eun-Joo Kim, Do-Hui Kim, Yong-Youp Park
  • Patent number: 8222519
    Abstract: A merocyanine dye is provided. The merocyanine dye is represented by formula (1). In the formula (1), A1 represents a divalent atomic group, n represents an integer of 1 to 3, A2 and A3 each independently represent an aromatic hydrocarbon ring or a heterocyclic ring having 3 to 18 carbon atoms, and R11 and R12 each independently represent a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, an aryl group having 6 to 18 carbon atoms, or a heterocyclic group having 3 to 18 carbon atoms.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: July 17, 2012
    Assignee: FUJIFILM Corporation
    Inventors: Kimiatsu Nomura, Rui Shen, Hideyuki Suzuki
  • Publication number: 20120009141
    Abstract: A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods.
    Type: Application
    Filed: August 7, 2009
    Publication date: January 12, 2012
    Applicant: PHARMASCIENCE INC.
    Inventors: Alain Laurent, Melanie Proulx, James B. Jaquith, Irina Denissova
  • Publication number: 20120009519
    Abstract: The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group which may have one or more halogen atoms, A1 represents a divalent connecting group, X1 represents a C2-C36 heterocyclic group and one or more —CH2— in the C2-C36 heterocyclic group can be replaced by —CO— or —O—, R2 is independently in each occurrence a halogen atom, a hydroxyl group, a C1-C24 hydrocarbon group, a C1-C12 alkoxy group, a C2-C4 acyl group or a C2-C4 acyloxy group, and m represents an integer of 0 to 10.
    Type: Application
    Filed: July 1, 2011
    Publication date: January 12, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Hyungjoo KIM, Akira KAMABUCHI, Yuichi MUKAI
  • Publication number: 20120007495
    Abstract: Disclosed are an organic material including a compound represented by the following Chemical Formula 1, and an organic light emitting device including the organic material. In Chemical Formula 1, A is an oxygen (O) atom or a sulfur (S) atom, M is a divalent or trivalent metal atom, R1 is an organic group, Y is a substituted or unsubstituted condensed polycyclic aromatic group, Z1 to Z4 are independently a carbon atom or a nitrogen atom, m is an integer ranging from 1 to 4, and n is 2 or 3.
    Type: Application
    Filed: October 26, 2010
    Publication date: January 12, 2012
    Applicant: Samsung Mobile Display Co., Ltd.
    Inventors: HAMADA Yuji, Kwan-Hee Lee
  • Publication number: 20110243850
    Abstract: Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent spectral characteristics and exhibiting excellent storage stability. The probe for a biological specimen contains, as an active agent, at least one kind of compound represented by a general formula (I).
    Type: Application
    Filed: December 24, 2009
    Publication date: October 6, 2011
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Takeshi Miyazaki, Masashi Hirose, Taketoshi Okubo, Kohei Watanabe, Tsuyoshi Nomoto, Toshio Tanaka, Yuhei Nishimura, Yasuhito Shimada, Norihiro Nishimura
  • Publication number: 20110196003
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Application
    Filed: March 14, 2011
    Publication date: August 11, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Publication number: 20110112073
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 12, 2011
    Applicant: DUKE UNIVERSITY
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Patent number: 7932276
    Abstract: The present invention provides a useful and highly safe agent for the treatment of chronic obstructive pulmonary disease, which contains, as the effective ingredient, at least one compound selected from the group consisting of thiazole derivatives and salts thereof represented by the general formula (1), wherein, R1 is a phenyl group which may have 1 to 3 lower alkoxy groups as the substituents on the phenyl ring; R2 is a pyridyl group which may have 1 to 3 carboxyl groups as the substituents on the pyridine ring.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: April 26, 2011
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazuo Sekiguchi, Katsumi Ikezono, Kazuhide Ohta, Takashi Maeda, Hisashi Nagamoto
  • Publication number: 20110052643
    Abstract: The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 7, 2009
    Publication date: March 3, 2011
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Qinglin Che, Nha Huu Vo, Shoujun Chen, Lijun Sun
  • Patent number: 7875639
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L2, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: January 25, 2011
    Assignee: Abbott Laboratories
    Inventors: Alan S. Florjancic, Michael J. Dart, Keith B. Ryther, Arturo Perez-Medrano, William A. Carroll, Meena V. Patel, Karin Rosemarie Tietje, Tongmei Li, Teodozyj Kolasa, Megan E. Gallagher, Sridhar Peddi, Jennifer M. Frost, Derek W. Nelson
  • Publication number: 20100331543
    Abstract: The quenching compounds of the invention are weakly luminescent cyanines that are substituted by one or more heteroaromatic quenching moieties. The quenching compounds of the invention exhibit little or no observable luminescence and efficiently quench a broad spectrum of luminescent compounds. The chemically reactive quenching compounds possess utility for labeling a wide variety of substances, including biomolecules. These labeled substances are highly useful for a variety of energy-transfer assays and applications.
    Type: Application
    Filed: August 30, 2010
    Publication date: December 30, 2010
    Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang
  • Patent number: 7759492
    Abstract: An enantioselective route to compounds of formula I is disclosed: The compounds of formula I are key intermediates in the synthesis of compounds useful in treatment of Alzheimer's disease.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: July 20, 2010
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Stephen Philip Keen, Steven Fraser Oliver, Gavin William Stewart
  • Publication number: 20100179330
    Abstract: Methods for the preparation of indene-based thiazolidinethiones are provided comprising contacting 1-amino-2,3-dihydro-1H-inden-2-ol, or a substituted derivative thereof, with an acid under suitable reaction conditions to provide a first intermediate; and contacting the first intermediate with an alkali xanthate in the presence of an alkali hydroxide under suitable reaction conditions to provide a compound of formula (III), wherein R1-R8 are defined herein.
    Type: Application
    Filed: January 11, 2010
    Publication date: July 15, 2010
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Horacio F. Olivo, Antonio Victor Osorio Lozada
  • Publication number: 20100151064
    Abstract: Described are compounds having a thiazolhydrazide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said thiazolhydrazide compounds can be used for prophylaxis and/or treatment of neurodegenerative diseases and conditions.
    Type: Application
    Filed: November 5, 2007
    Publication date: June 17, 2010
    Inventors: Eckhard Mandelkow, Eva-Maria Mandelkow, Markus Pickhardt, Jacek Biernat, David George Lloyd, Boris Schmidt, Gregor Larbig
  • Publication number: 20100113789
    Abstract: The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect.
    Type: Application
    Filed: September 30, 2005
    Publication date: May 6, 2010
    Applicants: FUJIFILM CORPORATION
    Inventors: Masataka Ihara, Kiyosei Takasu, Khanitha Pudhom, Hiroshi Kitaguchi, Masayuki Kawakami, Kozo Sato
  • Patent number: 7662840
    Abstract: This invention relates to a pharmaceutical composition containing 4-[(4-thiazolyl)phenoxyl]alkoxy-benzamidine derivatives expressed by the following formula 1 for the prevention and treatment of osteoporosis and more particularly, to the use of 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-iso-propyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine expressed by the following formula 1, which is known as an antagonist of leukotriene-B4 receptor, as a pharmaceutical composition for the prevention and treatment of osteoporosis. [Formula 1], wherein, R is a hydrogen atom or a hydroxy group.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: February 16, 2010
    Assignee: Dong Wha Pharmaceutical Co., Ltd.
    Inventors: Hong-Suk Suh, Jin-Soo Lee, Pan-Soo Kim, Yun-Ha Hwang, Jei-Man Ryu, Yong-Ho Chung, Eun-Joo Kim, Do-Hui Kim, Yong-Youp Park
  • Publication number: 20090318513
    Abstract: A compound represented by the general formula (I): wherein R1 is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5 is a hydrogen atom or the like; R6 and R7 are a hydrogen atom or the like; R8 is C1-C3 alkyl or the like; R9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.
    Type: Application
    Filed: August 27, 2009
    Publication date: December 24, 2009
    Inventors: Masami Takayama, Yutaka Yoshida
  • Patent number: 7618989
    Abstract: Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: November 17, 2009
    Assignee: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Patent number: 7582665
    Abstract: Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X1—Y1-Z1-W1??(I) wherein X1 is optionally substituted aryl, optionally substituted heteroaryl or the like; Y1 is —NRACO—(CH2)0-2— or the like (wherein RA is a hydrogen or the like); Z1 is optionally substituted phenylene or the like; and W1 is a group represeted by the below formula: wherein R1, R2, R3, and R4 are each independently a hydrogen atom, optionally substituted lower alkyl or the like, a broken line ( - - - ) represents the presence or absence of bond.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 1, 2009
    Assignee: Shionogi & Co., Ltd.
    Inventors: Hiroshi Takemoto, Takeshi Shiota, Masami Takayama
  • Publication number: 20090215841
    Abstract: This invention relates to the compound of Formula I and pharmaceutically acceptable salts thereof: (R)-N*6*-ethyl-6,7-dihydro-5H-indeno[5,6-d]thiazole-2,6-diamine This invention also relates to methods of making, methods of using, and pharmaceutical compositions comprising the compound of Formula I and salts thereof.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 27, 2009
    Applicant: ASTRAZENECA AB
    Inventors: William C. Blackwell, III, James Hulsizer, JianWei Liu, Gary Steelman, Rebecca Urbanek, Dan Widzowski, Ye Wu
  • Publication number: 20090182023
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Application
    Filed: June 18, 2007
    Publication date: July 16, 2009
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Publication number: 20090088490
    Abstract: A simultaneous two-photon absorption three-dimensional recording material includes at least one kind of dye having at least one polymerizable group.
    Type: Application
    Filed: September 26, 2008
    Publication date: April 2, 2009
    Applicant: FUJIFILM CORPORATION
    Inventors: Masaharu AKIBA, Hiroo TAKIZAWA
  • Publication number: 20090076278
    Abstract: The present invention provides novel organic compounds, which absorb the light in the ultra violet and the infrared regions, have improved light tolerance and solubility in solvents, and have thermal tolerance suitable for uses to which the organic compounds are applied, and provides uses of the same. The above objects are solved by providing indolenine compounds and methine dyes, which have a bis-indolenine skeleton composed of two indolenine rings linked together at their respective C-3 positions via a divalent linking group, and by providing optical recording media containing the methine dyes.
    Type: Application
    Filed: November 7, 2006
    Publication date: March 19, 2009
    Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO
    Inventors: Yasufumi Dan-Oh, Masahiko Toki, Kentaro Yano, Yasushi Aizawa